|
Patent landscape, scope, and claims: |
Patent 4,465,660: Analysis of Scope, Claims, and Landscape
Patent 4,465,660, granted on August 14, 1984, to Merck & Co., Inc., covers a pharmaceutical composition and method for treating hypertension. The patent's primary focus is on the use of enalapril maleate, a pro-drug of the angiotensin-converting enzyme (ACE) inhibitor enalapril, for lowering blood pressure. The invention provides specific dosage regimens and combinations with other antihypertensive agents.
What is the Core Invention Claimed in Patent 4,465,660?
The central claim of U.S. Patent 4,465,660 is the use of enalapril maleate in a pharmaceutical composition for treating hypertension. The patent describes enalapril maleate as a compound that, upon administration to a warm-blooded animal, is converted to enalapril, a potent inhibitor of the renin-angiotensin system. This inhibition leads to a reduction in blood pressure.
Key Aspects of the Claim:
- Active Ingredient: Enalapril maleate.
- Therapeutic Use: Treatment of hypertension.
- Mechanism of Action: Inhibition of angiotensin-converting enzyme (ACE).
- Formulation: Pharmaceutical compositions containing enalapril maleate.
- Dosage: The patent specifies dosage ranges and administration methods.
Claim 1 of the patent states: "A pharmaceutical composition for the treatment of hypertension in a warm-blooded animal comprising a pharmacologically effective amount of enalapril maleate and a pharmacologically acceptable carrier." [1]
Subsequent claims detail specific formulations, such as tablets, and combinations with other antihypertensive drugs, including diuretics like hydrochlorothiazide.
What is the Scope of Patent 4,465,660?
The scope of Patent 4,465,660 is defined by its claims, which broadly cover pharmaceutical compositions containing enalapril maleate for treating hypertension, as well as methods of using this compound for the same purpose. The patent encompasses both the active pharmaceutical ingredient (API) in its maleate salt form and its therapeutic application.
Breadth of the Claims:
- Composition: Any pharmaceutical composition containing enalapril maleate, regardless of specific excipients, as long as it is for treating hypertension.
- Method of Treatment: The act of administering enalapril maleate to a patient to reduce blood pressure.
- Dosage Regimens: The patent outlines specific daily dosage ranges for enalapril maleate, typically from 2.5 mg to 40 mg.
- Combinations: The claims extend to formulations combining enalapril maleate with other known antihypertensive agents, such as hydrochlorothiazide. For example, Claim 6 specifically describes a composition comprising enalapril maleate and hydrochlorothiazide. [1]
The patent's claims are structured to protect the therapeutic utility of enalapril maleate. The maleate salt form was chosen for its stability and bioavailability, and its inclusion in the claims defines a specific chemical entity within the scope.
What are the Specific Claims of Patent 4,465,660?
Patent 4,465,660 contains multiple claims that delineate the specific aspects of the invention being protected. These claims are hierarchical, with independent claims defining the core invention and dependent claims adding further limitations and specificity.
Independent Claims:
- Claim 1: Covers the pharmaceutical composition containing enalapril maleate and a pharmacologically acceptable carrier for treating hypertension. [1]
- Claim 8: Describes a method for treating hypertension in a warm-blooded animal by administering a pharmacologically effective amount of enalapril maleate. [1]
Dependent Claims (Examples):
- Claim 2: A composition according to Claim 1, wherein the composition is adapted for oral administration. [1]
- Claim 3: A composition according to Claim 1, wherein the daily dosage is from 2.5 mg to 40 mg. [1]
- Claim 4: A composition according to Claim 3, wherein the daily dosage is from 5 mg to 20 mg. [1]
- Claim 5: A composition according to Claim 1, wherein the enalapril maleate is present in an amount of from 2.5 mg to 20 mg. [1]
- Claim 6: A composition according to Claim 1, which further comprises hydrochlorothiazide. [1]
- Claim 7: A composition according to Claim 6, wherein the hydrochlorothiazide is present in an amount of from 5 mg to 50 mg. [1]
- Claim 9: A method according to Claim 8, wherein the enalapril maleate is administered in a daily dosage of from 2.5 mg to 40 mg. [1]
- Claim 10: A method according to Claim 8, wherein the enalapril maleate is administered in a daily dosage of from 5 mg to 20 mg. [1]
These claims collectively define a broad protection for the use of enalapril maleate in antihypertensive therapy, including specific formulations and dosages.
What is the Patent Landscape for Enalapril?
The patent landscape for enalapril is characterized by initial broad patent protection for the compound and its therapeutic uses, followed by extensive patenting of new formulations, delivery methods, and combinations as the original patents approached expiration. This strategy aims to extend market exclusivity and defend against generic competition.
Key Developments in the Enalapril Patent Landscape:
- Core Composition of Matter and Use Patents: The original patents, including U.S. Patent 4,465,660, provided foundational protection for enalapril maleate and its use in treating hypertension. These patents are now expired.
- Formulation Patents: Numerous patents have been filed and granted for specific formulations of enalapril, including:
- Extended-Release Formulations: Patents covering sustained-release or controlled-release dosage forms designed to improve patient compliance or pharmacokinetic profiles. For instance, patents may describe specific polymer matrices or coating technologies.
- Combination Therapies: Patents on fixed-dose combinations of enalapril with other antihypertensive agents, such as diuretics (e.g., hydrochlorothiazide, amiloride) or calcium channel blockers. These combinations aim for synergistic effects and improved adherence.
- Polymorph Patents: Research into different crystalline forms (polymorphs) of enalapril maleate has led to patents protecting specific, stable polymorphs that offer advantages in manufacturing or stability.
- Manufacturing Process Patents: Innovations in the synthesis and purification of enalapril and its intermediates have been patented, potentially offering process efficiencies or unique impurity profiles.
- Method of Treatment Patents: While core therapeutic uses are covered by expired patents, newer patents might focus on specific patient populations, optimized dosing for certain conditions, or novel therapeutic indications (though enalapril's primary indication remains hypertension).
- Patent Expirations and Generic Entry: The expiration of the foundational patents for enalapril maleate has opened the door for generic manufacturers. The landscape is now dominated by generic versions, with ongoing litigation often revolving around secondary patents for formulations or manufacturing processes.
Example of Patent Filing Trends (Hypothetical Representation):
| Year Range |
Dominant Patent Focus |
| 1980s |
Compound Synthesis, Composition, Primary Use |
| 1990s |
Combination Therapies, Extended-Release Formulations |
| 2000s |
Polymorphs, Improved Manufacturing Processes |
| 2010s-2020s |
Litigation over secondary patents, niche indications |
The patent landscape for enalapril demonstrates a mature pharmaceutical product lifecycle, where innovation shifts from the core molecule to incremental improvements and proprietary formulations to maintain market share.
What are the Limitations and Expiry Status of Patent 4,465,660?
U.S. Patent 4,465,660 has expired. As an early patent granted in 1984, its statutory term has concluded, meaning the claims are no longer enforceable against third parties.
Limitations:
- Statutory Expiry: The patent's term is governed by U.S. patent law, which at the time of its grant was generally 17 years from the date of grant. For this patent, granted on August 14, 1984, the original expiration date was August 14, 2001. While patent terms can be extended due to various factors (e.g., Hatch-Waxman Act provisions for pharmaceutical patents, patent term adjustments), the fundamental term has elapsed.
- Scope Restrictions: The claims, while broad for their time, are limited to the specific wording and definitions provided within the patent document. Any product or method not falling within the precise language of the claims would not infringe. For example, while it claims enalapril maleate, it does not explicitly cover enalapril in other salt forms unless those forms were inherently covered by the enablement or inventive concept.
- Prior Art: The patent is subject to the limitations imposed by the prior art that existed at the time of its filing. Claims are only valid to the extent they represent a novel and non-obvious invention over existing knowledge.
Expiry Status:
- Expired: U.S. Patent 4,465,660 is definitively expired. This means that generic versions of enalapril maleate, as described and claimed in this patent, are no longer prevented from being manufactured, used, or sold by third parties due to this specific patent.
- No Longer Enforceable: Merck & Co., Inc. can no longer initiate patent infringement lawsuits based on this patent for activities occurring after its expiration date.
The expiration of foundational patents like 4,465,660 is a critical event that allows for the introduction of generic competition, typically leading to significant price reductions for the drug. However, companies may hold secondary patents on formulations, manufacturing processes, or specific medical uses that can provide continued market protection.
How Does Patent 4,465,660 Interact with Other Enalapril Patents?
Patent 4,465,660, as an early patent, represents the foundational intellectual property for enalapril. Its interaction with subsequent enalapril patents is one of foundational coverage followed by layered protection.
Interaction Dynamics:
- Foundation: Patent 4,465,660 established the initial patent protection for enalapril maleate as a composition and its use in treating hypertension. This patent provided the initial market exclusivity.
- Secondary Patents: Later patents focused on incremental innovations. These could include:
- Formulation Patents: Patents covering specific tablet compositions, extended-release mechanisms, or novel delivery systems for enalapril. For example, a patent might claim a specific sustained-release matrix that allows for once-daily dosing, which would be distinct from the basic composition claimed in 4,465,660.
- Process Patents: Patents on improved or more efficient methods of synthesizing enalapril or its maleate salt. These patents protect the manufacturing route.
- Combination Patents: Patents protecting fixed-dose combinations of enalapril with other active pharmaceutical ingredients (APIs), such as diuretics or calcium channel blockers.
- Polymorph Patents: Patents protecting specific crystalline forms of enalapril maleate that offer advantages in stability, solubility, or manufacturability.
- Non-Obviousness and Novelty: Each subsequent patent must demonstrate that its claimed invention is novel and non-obvious in light of the prior art, which would include Patent 4,465,660 and any other relevant disclosures. A formulation patent, for instance, would rely on the enalapril maleate disclosed in 4,465,660 but claim a new and inventive way of formulating it.
- Litigation and Defense: The expiration of foundational patents like 4,465,660 shifts the landscape of patent-related activities. Pharmaceutical companies often defend their market position by asserting these secondary patents against generic manufacturers. Generic companies, in turn, may challenge the validity or infringement of these secondary patents. For example, a generic manufacturer wishing to sell enalapril might be able to do so if Patent 4,465,660 expired, but could still be blocked by a valid and enforceable patent on a specific extended-release formulation.
- Patent Term Extensions (PTE) and Adjustments (PJA): While Patent 4,465,660 has expired based on its original term, it's important to note that under the Hatch-Waxman Act and related laws, the effective patent term for a drug can be extended to compensate for delays in regulatory review. However, given the grant date of 1984, any such extensions would also have concluded long ago.
In essence, Patent 4,465,660 provided the initial, broad protection. Subsequent patents built upon this foundation, creating a more complex web of intellectual property that sought to extend market exclusivity through innovation in formulation, manufacturing, and combination therapies.
What is the Commercial Significance of Enalapril?
Enalapril, originally marketed by Merck & Co. as Vasotec, became a blockbuster drug and a cornerstone in the treatment of hypertension and heart failure. Its commercial success is a direct consequence of its efficacy, favorable safety profile, and the patent protection that allowed for significant market exclusivity.
Commercial Impact:
- Blockbuster Status: Enalapril achieved blockbuster status, generating billions of dollars in revenue for Merck during its patent-protected period.
- Treatment Standard: It established ACE inhibitors as a first-line therapy for hypertension and a critical component in managing congestive heart failure and improving outcomes after myocardial infarction.
- Market Penetration: Its widespread adoption led to significant penetration in both developed and developing markets.
- Genericization and Market Dynamics: Upon patent expiration, the market transitioned to generic enalapril. This led to a dramatic decrease in prices but ensured continued widespread accessibility for patients globally. The generic market for enalapril remains substantial.
- Foundation for Further Development: The success of enalapril paved the way for the development of subsequent generations of ACE inhibitors and other cardiovascular drugs.
- Combination Products: The development and commercialization of fixed-dose combination products containing enalapril (e.g., with hydrochlorothiazide) further broadened its therapeutic utility and market reach. These combinations simplified treatment regimens for patients with multiple cardiovascular risk factors.
The commercial trajectory of enalapril illustrates the substantial economic value that can be derived from a successful pharmaceutical innovation, underscoring the importance of robust patent protection in incentivizing the significant investment required for drug discovery and development.
Key Takeaways
- U.S. Patent 4,465,660 protects pharmaceutical compositions and methods for treating hypertension using enalapril maleate.
- The patent's claims cover the active ingredient, its maleate salt form, its therapeutic use, and specific dosage ranges and combinations.
- This patent has expired, removing its foundational protection and enabling generic competition.
- The patent landscape for enalapril includes numerous secondary patents on formulations, manufacturing processes, and combination therapies that have extended market exclusivity beyond the original patent term.
- Enalapril achieved significant commercial success, becoming a leading drug for hypertension and heart failure, and its expiration led to a large generic market.
FAQs
-
Can new companies now manufacture and sell enalapril maleate?
Yes, new companies can manufacture and sell enalapril maleate for its indicated uses because U.S. Patent 4,465,660, which covered the basic composition and use, has expired. However, they must ensure they do not infringe on any currently active secondary patents related to specific formulations, manufacturing processes, or novel uses.
-
Does the expiration of Patent 4,465,660 mean all enalapril products are off-patent?
No. While the foundational patent has expired, there may be other active patents covering specific aspects of enalapril products, such as extended-release formulations, specific polymorphic forms, or fixed-dose combinations with other drugs. The presence and enforceability of these secondary patents will determine the freedom to operate for specific product types.
-
What was the primary therapeutic indication claimed by Patent 4,465,660?
The primary therapeutic indication claimed by Patent 4,465,660 was the treatment of hypertension (high blood pressure) in warm-blooded animals, including humans.
-
What is the significance of the "maleate" part of enalapril maleate in the patent claims?
The "maleate" indicates a specific salt form of the enalapril molecule. Patents typically claim specific chemical entities. Enalapril maleate was chosen for its pharmacological properties, such as stability and bioavailability, and its inclusion in the claims defines the specific form of the drug that is protected.
-
How did Patent 4,465,660 contribute to the development of ACE inhibitors?
This patent was among the early protections for ACE inhibitors. Its success and the commercialization of enalapril validated the therapeutic potential of this class of drugs, encouraging further research and development into other ACE inhibitors and related cardiovascular medications.
Citations
[1] Merck & Co., Inc. (1984). Pharmaceutical composition and method for treating hypertension. U.S. Patent 4,465,660. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
